In this episode, we speak with Susan Tousi, CEO of DELFI Diagnostics and former Chief Commercial Officer at Illumina, about using fragmentomics and AI to detect cancer through a simple blood draw. Susan explains how Delfi's whole-genome approach analyzes the structural chaos of tumor-derived DNA rather than hunting for specific mutations, dramatically reducing cost while maintaining sensitivity. We discuss their first product, First Look Lung, which achieves 75% sensitivity for stage one lung cancer, and how the platform can expand to detect the seven deadliest cancers using the same laboratory workflow with different AI algorithms.